The COVID-19 pandemic has highlighted a number of deficiencies within the US health care system, chief among them the vast gulf of inequality between different ethnic groups and geographic areas, a gulf that has resulted in the virus causing significant disease and death among Black, Latino and Native American communities. A consequence of that inequality is that the populations enrolled into clinical trials have historically often not properly reflected the ethnic makeup of the country.
The pandemic has drawn significant attention to the issue of clinical trial diversity, and as a result, several drug makers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
